Immunic
IMUX
60 hedge funds and large institutions have $116M invested in Immunic in 2021 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 29 increasing their positions, 9 reducing their positions, and 8 closing their positions.
222% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 9
23% more call options, than puts
Call options by funds: $1.24M | Put options by funds: $1.01M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.06% less ownership
Funds ownership: 4.39% → 4.34% (-0.06%)
5% less funds holding
Funds holding: 63 → 60 (-3)
22% less capital invested
Capital invested by funds: $148M → $116M (-$32.6M)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.42M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.41M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.3M |
| 4 |
Millennium Management
New York
|
+$1.11M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$900K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.18M |
| 3 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$520K |
| 4 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$470K |
| 5 |
Two Sigma Advisers
New York
|
-$423K |
IMUX Hedge Fund Activity: Q2 2021 in Review
60 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q2 2021, worth a combined $116M — down 22% from $148M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of IMUX and 5 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 29 added.
The largest buyer was BlackRock, adding an estimated $5.42M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $6.9M sold.
- 60 institutional investors held Immunic (IMUX) as of Q2 2021, down from 63 in Q1 2021.
- Funds reported $116M of Immunic stock for Q2 2021, down 22% quarter-over-quarter.
- 5 funds opened new Immunic positions in Q2 2021 and 8 closed out, a net change of -3 holders.
- The largest Immunic buyer in Q2 2021 was BlackRock, an estimated $5.42M added.
- The largest Immunic seller in Q2 2021 was Point72 Asset Management, an estimated $6.9M sold.
Based on aggregated 13F filings for Q2 2021.